Literature DB >> 23627282

Development and therapeutic implications of selective histone deacetylase 6 inhibitors.

Jay H Kalin1, Joel A Bergman.   

Abstract

This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627282     DOI: 10.1021/jm4001659

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

Review 1.  An overview of naturally occurring histone deacetylase inhibitors.

Authors:  Bumki Kim; Jiyong Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

3.  Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.

Authors:  Sanil Bhatia; Viktoria Krieger; Michael Groll; Jeremy D Osko; Nina Reßing; Heinz Ahlert; Arndt Borkhardt; Thomas Kurz; David W Christianson; Julia Hauer; Finn K Hansen
Journal:  J Med Chem       Date:  2018-11-08       Impact factor: 7.446

4.  Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.

Authors:  Chung-Pu Wu; Ya-Ju Hsieh; Megumi Murakami; Shahrooz Vahedi; Sung-Han Hsiao; Ni Yeh; An-Wei Chou; Yan-Qing Li; Yu-Shan Wu; Jau-Song Yu; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2018-07-17       Impact factor: 5.858

5.  Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.

Authors:  Liudmila Cebotaru; Qiangni Liu; Murali K Yanda; Clement Boinot; Patricia Outeda; David L Huso; Terry Watnick; William B Guggino; Valeriu Cebotaru
Journal:  Kidney Int       Date:  2016-03-25       Impact factor: 10.612

6.  Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.

Authors:  Nina Reßing; Melf Sönnichsen; Jeremy D Osko; Andrea Schöler; Julian Schliehe-Diecks; Alexander Skerhut; Arndt Borkhardt; Julia Hauer; Matthias U Kassack; David W Christianson; Sanil Bhatia; Finn K Hansen
Journal:  J Med Chem       Date:  2020-09-01       Impact factor: 7.446

7.  Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.

Authors:  Dong Lu; Juan Yan; Lang Wang; Hongchun Liu; Limin Zeng; Minmin Zhang; Wenwen Duan; Yinchun Ji; Jingchen Cao; Meiyu Geng; Aijun Shen; Youhong Hu
Journal:  ACS Med Chem Lett       Date:  2017-07-18       Impact factor: 4.345

8.  A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.

Authors:  Mar Cuadrado-Tejedor; Carolina Garcia-Barroso; Juan A Sánchez-Arias; Obdulia Rabal; Marta Pérez-González; Sara Mederos; Ana Ugarte; Rafael Franco; Victor Segura; Gertrudis Perea; Julen Oyarzabal; Ana Garcia-Osta
Journal:  Neuropsychopharmacology       Date:  2016-08-23       Impact factor: 7.853

9.  Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.

Authors:  Nina Reßing; Viktoria Marquardt; Christoph G W Gertzen; Andrea Schöler; Alexander Schramm; Thomas Kurz; Holger Gohlke; Achim Aigner; Marc Remke; Finn K Hansen
Journal:  Medchemcomm       Date:  2018-10-23       Impact factor: 3.597

10.  Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.

Authors:  Sida Shen; Veronick Benoy; Joel A Bergman; Jay H Kalin; Mariana Frojuello; Giulio Vistoli; Wanda Haeck; Ludo Van Den Bosch; Alan P Kozikowski
Journal:  ACS Chem Neurosci       Date:  2015-12-07       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.